Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17205182rdf:typepubmed:Citationlld:pubmed
pubmed-article:17205182lifeskim:mentionsumls-concept:C0042153lld:lifeskim
pubmed-article:17205182lifeskim:mentionsumls-concept:C0002508lld:lifeskim
pubmed-article:17205182lifeskim:mentionsumls-concept:C1333707lld:lifeskim
pubmed-article:17205182lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:17205182lifeskim:mentionsumls-concept:C1521827lld:lifeskim
pubmed-article:17205182pubmed:issue2lld:pubmed
pubmed-article:17205182pubmed:dateCreated2007-1-5lld:pubmed
pubmed-article:17205182pubmed:abstractTextA family of previously reported ring-closing metathesis (RCM)-derived macrocycles that exhibit potent Grb2 SH2 domain-binding affinity is characterized by stereoselectively-introduced upper ring junctions that bear bicyclic aryl substituents. However, the synthetic complexity of these macrocycles presents a potential limit to their therapeutic application. Therefore, the current study was undertaken to simplify these macrocycles through the use of achiral 4-pentenylamides as ring-forming components. A series of macrocycles (5a-f) was prepared bearing both open and cyclic constructs at the upper ring junction. The Grb2 SH2 domain-binding affinities of these macrocycles varied, with higher affinities being obtained with cyclo-substituents. The most potent analogue (5d) contained a cyclohexyl group and exhibited Grb2 SH2 domain-binding affinity (K(D) = 1.3 nM) that was nearly equal to the parent macrocycle (2), which bore a stereoselectively-introduced naphthylmethyl substituent at the upper ring junction (K(D) = 0.9 nM). The results of this study advance design considerations that should facilitate the development of Grb2 SH2 domain-binding antagonists.lld:pubmed
pubmed-article:17205182pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17205182pubmed:languageenglld:pubmed
pubmed-article:17205182pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17205182pubmed:citationSubsetIMlld:pubmed
pubmed-article:17205182pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17205182pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17205182pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17205182pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17205182pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17205182pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17205182pubmed:statusMEDLINElld:pubmed
pubmed-article:17205182pubmed:monthJanlld:pubmed
pubmed-article:17205182pubmed:issn1477-0520lld:pubmed
pubmed-article:17205182pubmed:authorpubmed-author:JinLLlld:pubmed
pubmed-article:17205182pubmed:authorpubmed-author:BurkeTerrence...lld:pubmed
pubmed-article:17205182pubmed:authorpubmed-author:FisherRobert...lld:pubmed
pubmed-article:17205182pubmed:authorpubmed-author:BottaroDonald...lld:pubmed
pubmed-article:17205182pubmed:authorpubmed-author:WorthyKaren...lld:pubmed
pubmed-article:17205182pubmed:authorpubmed-author:GiubellinoAle...lld:pubmed
pubmed-article:17205182pubmed:authorpubmed-author:BinduLakshman...lld:pubmed
pubmed-article:17205182pubmed:issnTypePrintlld:pubmed
pubmed-article:17205182pubmed:day21lld:pubmed
pubmed-article:17205182pubmed:volume5lld:pubmed
pubmed-article:17205182pubmed:ownerNLMlld:pubmed
pubmed-article:17205182pubmed:authorsCompleteYlld:pubmed
pubmed-article:17205182pubmed:pagination367-72lld:pubmed
pubmed-article:17205182pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:meshHeadingpubmed-meshheading:17205182...lld:pubmed
pubmed-article:17205182pubmed:year2007lld:pubmed
pubmed-article:17205182pubmed:articleTitleUtilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis.lld:pubmed
pubmed-article:17205182pubmed:affiliationLaboratory of Medicinal Chemistry, Bldg. 376 Boyles St., Center for Cancer Research, NCI-Frederick, National Institutes of Health, Frederick, MD 21702, USA.lld:pubmed
pubmed-article:17205182pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17205182pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
pubmed-article:17205182pubmed:publicationTypeResearch Support, N.I.H., Intramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17205182lld:pubmed